Brief: Sorrento Therapeutics Completes Enrollment Of Phase 2 Clinical Trial Of Resiniferatoxin (RTX) For Treatment Of Knee Pain In Moderate To Severe Osteoarthritis Of The Knee (OAK) Patients
26/09/2022 14:49
Sept 26 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO THERAPEUTICS COMPLETES ENROLLMENT OF PHASE 2
CLINICAL
TRIAL OF RESINIFERATOXIN (RTX) FOR TREATMENT OF KNEE PAIN IN
MODERATE TO SEVERE OSTEOARTHRITIS OF THE KNEE (OAK) PATIENTS
* SORRENTO THERAPEUTICS - PLANS TO CONDUCT AN END OF PHASE 2
MEETING WITH FDA FOR RTX PROGRAM AS SOON AS INITIAL TOP LINE
DATA IS AVAILABLE
* SORRENTO THERAPEUTICS INC - INITIAL EFFICACY DATA ON PAIN
RELIEF
PARAMETERS EXPECTED TO BE AVAILABLE IN Q2 2023
Source text for Eikon: ID:nGNX5nJM0g
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20